Liver X Receptor Alpha (LXRα; NR1H3)

The protein encoded by this gene belongs to the NR1 subfamily of the nuclear receptor superfamily. The NR1 family members are key regulators of macrophage function, controlling transcriptional programs involved in lipid homeostasis and inflammation. This protein is highly expressed in visceral organs, including liver, kidney and intestine. It forms a heterodimer with retinoid X receptor (RXR), and regulates expression of target genes containing retinoid response elements. Studies in mice lacking this gene suggest that it may play an important role in the regulation of cholesterol homeostasis. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.

[Provided by RefSeq, Oct 2011]

NRR Pathway

lxr-pathway

Liver X Receptor Alpha Structure

mmdbimage-6_med

(From Structure)

Link

 

(From Aceview)

There are 111 articles specifically referring to this gene in PubMed. Functionally, the gene has been tested for association to diseases (Cholesterol, HDL/blood*; Coronary Artery Disease; Diabetes mellitus, type 2; Dyslipidemias; Gallstones; Genetic Predisposition to Disease; Hepatomegaly; hyperlipidemia, familial combined; Liver Neoplasms; obesity; Psoriasis; Tuberculosis, Pulmonary), proposed to participate in pathways (FXR and LXR Regulation of Cholesterol Metabolism, Mechanism of Gene Regulation by Peroxisome Proliferators via PPARa(alpha), PPAR signaling pathway) and processes (apoptotic cell clearance, negative regulation of cholesterol storage, negative regulation of lipid transport, negative regulation of macrophage derived foam cell differentiation, negative regulation of pinocytosis and 10 others). Proteins are expected to have molecular functions (DNA binding, ligand-dependent nuclear receptor activity, protein binding, sterol response element binding, transcription coactivator activity and 6 others) and to localize in various compartments (cytoplasm, membrane, nucleus). Putative protein interactors have been described (ACTN1, BARD1, CEP350, EDF1, FOXO3, ING3, NCOA3, NCOA6, NCOR1, NR0B2 and 10 others). 

(From HuGENavigator)

  • Cardiovascular Diseases 
  • Diabetes Mellitus, Type 2 
  • Coronary Artery Disease 
  • Inflammation 
  • Metabolic Syndrome X 
  • Myocardial Ischemia 
  • Polycystic Ovary Syndrome 
  • Pre-Eclampsia 
  • Prediabetic State 
  • Alzheimer Disease 
  • Insulin Resistance 
  • Kidney Failure, Chronic 
  • Lymphoma, Non-Hodgkin 
  • Hypercholesterolemia 
  • Hyperlipidemia, Familial Combined 
  • Hypertension 
  • Coronary Disease 
  • Dementia 
  • Cerebrovascular Disorders 
  • Colorectal Neoplasms 
  • Dyslipidemias 
  • Edema 
  • Gallbladder Neoplasms 
  • Gallstones 

Assay Kits and Services are available from INDIGO Biosciences.

Kits are offered in different assay formats to accommodate researchers’ needs: 3x 32, 1x 96, and 1x 384 assay formats for screening small numbers of test compounds, as well as custom bulk reagents for HTS applications. Assay systems are all inclusive, providing reporter cells, optimized growth media, media for diluting test compounds, a positive-control agonist, luciferase detection reagent, a white assay plate, a detailed protocol, and a protocol quick guide. All kits are shipped on dry ice.

LXRα Reporter Cells are prepared using INDIGO’s proprietary CryoMite™ process. This cryo-preservation method yields high cell viability post-thaw, and provides the convenience of immediately dispensing healthy, division-competent reporter cells into assay plates. There is no need for intermediate spin-and-wash steps, viability determinations, or cell titer adjustments.

The principle application of this assay product is in the screening of test samples to quantify functional activities, either agonist or antagonist, that they may exert against the liver x receptor. This kit product is an all-inclusive assay system that includes, in addition to LXRα Reporter Cells, two optimized media for use during cell culture and (optionally) in diluting the test samples, a reference agonist, Luciferase Detection Reagent, a cell culture-ready assay plate, and a detailed protocol.

LXRA; LXR-a; RLD-1

(From Aceview)

The gene contains 35 distinct gt-ag introns. Transcription produces 36 different mRNAs, 34 alternatively spliced variants and 2 unspliced forms. There are 7 probable alternative promotors, 4 non overlapping alternative last exons and 6 validated alternative polyadenylation sites (see the diagram). The mRNAs appear to differ by truncation of the 5′ end, truncation of the 3′ end, presence or absence of 29 cassette exons, overlapping exons with different boundaries, splicing versus retention of 11 introns. 706 bp of this gene are antisense to spliced gene ACP2.aAug10, raising the possibility of regulated alternate expression. 3 variants were isolated in vivo, despite the fact that they are predicted targets of nonsense mediated mRNA decay (NMD). Efficacy of translation may be reduced by the presence of a shorter translated product (uORF) initiating at an AUG upstream of the main open reading frame (in variant aAug10, bAug10, dAug10, fAug10, jAug10).

image-17_med

(From STRINGS)

ACTN1, BARD1, CEP350, EDF1, FOXO3, ING3, NCOA3, NCOA6, NCOR1, NR0B2

(From KEGG)

None noted

(From BioGPS)203920_at_med